Table 2 LS mean changes (95% CI) from baseline in the 52‐week base studies (analysis of time‐weighted average response to treatment).
| Treatment group | WOMAC pain subscale (VAS*) | WOMAC physical function subscale (VAS*) | Patient global assessment of disease status (VAS*) |
|---|---|---|---|
| Part I (12‐week treatment period) | |||
| Placebo | −15.31 (−19.25 to −11.37) | −10.27 (−14.19 to −6.35) | −13.38 (−17.51 to −9.26) |
| Etoricoxib 60 mg | −27.94 (−30.03 to −25.85) | −22.81 (−24.89 to −20.74) | −26.39 (−28.57 to −24.21) |
| Naproxen 1000 mg | −28.57 (−30.68 to −26.47) | −23.70 (−25.78 to −21.61) | −26.46 (−28.66 to −24.26) |
| Parts I and II (52‐week treatment period; in patients receiving the same treatment for 52 weeks) | |||
| Etoricoxib 60 mg | −31.03 (−33.19 to −28.86) | −25.96 (−28.24 to −23.69) | −27.58 (−29.83 to −25.32) |
| Naproxen | −30.60 (−32.82 to −28.39) | −26.06 (−28.39 to −23.73) | −27.82 (−30.14 to −25.51) |
WOMAC, Western Ontario and McMaster Universities OA Index; VAS, visual analogue scale.
*0–100 mm scale.